-
Symposium highlights supplements, menopause, and other trending topics in nutrition
Nutrition experts, including Kevin Klatt, PhD, RD, and Hillary Wright, MEd, RDN, LDN, analyzed several diet-related considerations that could have downstream implications for an individual’s diabetes management.
-
Debate weighs whether BMI should remain central to obesity diagnosis
Francesco Rubino, MD, spoke in favor of moving beyond body mass index in diagnosing obesity. Leigh Perreault, MD, defended the long-time cornerstone of obesity diagnosis.
Scientific Sessions Newsmakers
-
Oral small-molecule GLP-1 RA improves blood glucose and weight reduction
The VISTA and SOLSTICE phase 2b trials evaluated the use of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) elecoglipron in adults. Melanie Davies, CBE, MBChB, MD, FRCP, FRCGP, FMedSci, and Vanita R. Aroda, MD, shared the latest study data.
-
ACHIEVE results show A1C reduction, weight loss in type 2 diabetes
Investigators aim to use orforglipron to address the limitations of injectable GLP-1 RAs. The primary goal is to provide an alternative that meets health needs without the logistical challenges of current treatments, said Rodolfo J. Galindo, MD.
-
Outstanding Educator in Diabetes Award recipient: Value the stories behind the numbers
In her award lecture, Diana Isaacs, PharmD, BCACP, CDCES, BC-ADM, FADCES, FCCP, advocated embracing new tools and technology while keeping the people living with diabetes central to new approaches to care.
-
Kelly West lecturer outlines next steps for more precise definitions, preventions, and treatments for type 2 diabetes
Mohammed K. Ali, MD, MSc, MBA, who was being honored for his contributions to diabetes epidemiology, said the field is poised to move beyond a “one-size-fits-all” approach to diabetes public health policies.
-
Glucagon/GLP-1 receptor dual agonist demonstrates efficacy for obesity and MASLD
Matthias H. Tschöp, MD, and other researchers detailed phase 3 results of SYNCHRONIZE-1 and SYNCHRONIZE-MASLD showing that survodutide leads to significant weight loss, reduction in liver fat, and other health improvements.
-
REIMAGINE trials demonstrate efficacy of combination therapy for treating type 2 diabetes
Donna Ryan, MD, and other panelists reported on new data from phase 3 trials evaluating the combination of cagrilintide, which mimics amylin, and semaglutide, a glucagon-like peptide-1 receptor agonist, in adults.
Presenter Profiles
